66 Results for "

B-raf kinase

" in MedChemExpress (MCE) Product Catalog:
Products (66)

66 Results for "B-raf kinase" in MCE Product Catalog:

105
105 Publications Verification
Cat. No.: HY-12057
CAS No.: 918504-65-1
Purity:  99.85%
Synonyms: PLX4032; RG7204; RO5185426
Target:  

Raf Autophagy

Research Areas:  

Cancer

Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAF V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .
loading...
    loading...
53
53 Cited Publications
Cat. No.: HY-10320
CAS No.: 285983-48-4
Purity:  99.76%
Synonyms: BIRB 796
Target:  

p38 MAPK Raf Autophagy

Research Areas:  

Inflammation/Immunology Cancer

Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-11004
CAS No.: 878739-06-1
Purity:  99.44%
Target:  

Raf Apoptosis

Research Areas:  

Cancer

AZ 628 is a pan-Raf kinase inhibitor with IC50s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-10966
CAS No.: 405554-55-4
Purity:  99.77%
Target:  

Raf Apoptosis

SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-18957
CAS No.: 1446090-79-4
Synonyms: BGB-283
Target:  

EGFR Raf

Research Areas:  

Cancer

Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRaf V600E and EGFR, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-14177
CAS No.: 1093100-40-3
Purity:  98.03%
Target:  

Raf

Research Areas:  

Cancer

Raf inhibitor 1 is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-Raf WT, B-Raf V600E, and C-Raf, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-14177A
CAS No.: 1191385-19-9
Target:  

Raf

Research Areas:  

Cancer

B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-Raf WT, B-Raf V600E, and C-Raf, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12787
CAS No.: 303727-31-3
Purity:  98.67%
Target:  

Raf Autophagy

Research Areas:  

Cancer

L-779450 is a potent and selective B-Raf kinase inhibitor with a Kd of 2.4 nM.
loading...
    loading...
Cat. No.: HY-18832
CAS No.: 1135205-94-5
Target:  

Ephrin Receptor

Research Areas:  

Cancer

AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf .
loading...
    loading...
Cat. No.: HY-111940
CAS No.: 2274819-46-2
Purity:  97.23%
Synonyms: LUT014
Omzirafenib (LUT014) is a topical inhibitor targeting BRAF that cannot pass through the blood-brain barrier. Omzirafenib inhibits BRAF kinase and abnormally activates the MAPK/ERK signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. Omzirafenib is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. Omzirafenib can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy .
loading...
    loading...
Cat. No.: HY-107779
CAS No.: 1392429-79-6
Purity:  99.16%
Target:  

Raf

Research Areas:  

Cancer

BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF V600E-mutant, the WT BRAF and CRAF kinases with IC50s of 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibits SRC family kinases .
loading...
    loading...
Cat. No.: HY-12291
CAS No.: 1315329-43-1
Purity:  99.69%
Synonyms: HMSL 10017-101-1
Target:  

Raf Apoptosis

Research Areas:  

Cancer

HG6-64-1 (HMSL 10017-101-1) is a B-raf kinase modulator.HG6-64-1 modulates B-raf kinase activity, including the V600E mutant form and the drug-resistant gatekeeper mutation T529I. HG6-64-1 is a germinal center kinase inhibitor. HG6-64-1 induces cell cycle arrest and apoptosis. HG6-64-1 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .
loading...
    loading...
Cat. No.: HY-137487
CAS No.: 2417296-84-3
Purity:  98.02%
Target:  

PROTACs Raf

Research Areas:  

Cancer

PROTAC BRAF-V600E degrader-1 is a BRAF-V600E-selective PROTAC degrader and inhibitor. PROTAC BRAF-V600E degrader-1 induces degradation of BRAF-V600E via the cellular ubiquitin proteasome system, sparing wild-type BRAF. PROTAC BRAF-V600E degrader-1 suppresses the MEK/ERK kinase cascade in melanoma cells. PROTAC BRAF-V600E degrader-1 impairs growth of melanoma cells in culture. PROTAC BRAF-V600E degrader-1 can be used for the research of melanoma, colon cancer .
loading...
    loading...
Cat. No.: HY-77113
CAS No.: 918504-27-5
Target:  

Raf

Research Areas:  

Cancer

B-Raf IN 11 is a B-Raf V600E mutant kinase inhibitor with an IC50 of 76 nM, and exhibits an IC50 of 238 nM against wild-type B-Raf kinase. B-Raf IN 11 inhibits the kinase activities of B-Raf V600E mutant and wild-type B-Raf kinase. B-Raf IN 11 is applicable to relevant research on colorectal cancer .
loading...
    loading...
Cat. No.: HY-117273
CAS No.: 942507-42-8
Purity:  99.77%
Target:  

Raf Autophagy

Research Areas:  

Cancer

AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity .
loading...
    loading...
Cat. No.: HY-18227
CAS No.: 950736-05-7
Target:  

Raf

Research Areas:  

Cancer

B-Raf IN 1 is a potent and selective B-Raf kinase inhibitor with an IC50 of 24 nM.
loading...
    loading...
Cat. No.: HY-P10438
Target:  

Raf

Research Areas:  

Cancer

TAT-Braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by TAT-Braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of RAF kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .
loading...
    loading...
Cat. No.: HY-136567
CAS No.: 1777832-90-2
Purity:  99.81%
Target:  

Raf

Research Areas:  

Cancer

TBAP-001 (Synthesis 13), extracted from patent WO2015075483A1, is a pan-RAF kinase inhibitor, with an IC50 of 62 nM in BRAF V600E kinase assay .
loading...
    loading...
Cat. No.: HY-117658
CAS No.: 1301761-96-5
Purity:  99.52%
Target:  

MAP3K

Research Areas:  

Cardiovascular Disease

GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 μM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue .
loading...
    loading...
Cat. No.: HY-P10436
CAS No.: 2411851-64-2
Target:  

Raf

Research Areas:  

Cancer

Braftide is an allosteric inhibitor for BRAF kinase by targeting the dimer interface of BRAF kinase and inhibiting the formation of BRAF dimers. Braftide inhibits wild-type BRAF and oncogenic BRAF G469A with IC50 of 364 nM and 172 nM, respectively. Braftide inhibits MAPK signaling pathway, inhibits proliferation of KRAS mutant tumor cells (EC50 is 7.1 and 6.6 μM, for HCT116 and HCT-15), in combination of TAT sequence. Braftide can be used for cancer research .
loading...
    loading...